Public Sector Pension Investment Board Buys 10,496 Shares of Johnson & Johnson $JNJ

Public Sector Pension Investment Board raised its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 426,060 shares of the company’s stock after acquiring an additional 10,496 shares during the period. Public Sector Pension Investment Board’s holdings in Johnson & Johnson were worth $105,644,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Outlook Capital Management LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $28,000. Matrix Trust Co lifted its position in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after buying an additional 54 shares during the last quarter. Navigoe LLC lifted its position in shares of Johnson & Johnson by 60.4% during the 3rd quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after buying an additional 55 shares during the last quarter. Montgomery Financial Services LLC acquired a new stake in Johnson & Johnson in the second quarter valued at about $43,000. Finally, Hanseatic Management Services Inc. acquired a new stake in Johnson & Johnson in the third quarter valued at about $52,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 1.5%

Shares of JNJ stock opened at $278.42 on Wednesday. The firm has a market capitalization of $670.23 billion, a P/E ratio of 42.18, a P/E/G ratio of 2.79 and a beta of 0.22. Johnson & Johnson has a twelve month low of $198.53 and a twelve month high of $290.25. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock’s fifty day simple moving average is $267.31 and its 200 day simple moving average is $250.38.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analysts’ expectations of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts predict that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 1.9%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on JNJ shares. Guggenheim reissued a “buy” rating and set a $287.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 7th. Royal Bank Of Canada reduced their price target on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 14th. Bank of America reaffirmed a “neutral” rating and set a $278.00 price target on shares of Johnson & Johnson in a report on Tuesday, September 29th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, Leerink Partners dropped their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $275.92.

View Our Latest Research Report on Johnson & Johnson

Key Johnson & Johnson News

Here’s some of the latest news about JNJ:

  • Positive Sentiment: J&J’s planned acquisition of Ollin Biosciences adds a Phase 3 candidate for retinal diseases, including wet age-related macular degeneration and diabetic macular edema. The deal includes $2.2 billion upfront and up to about $1.1 billion in milestone payments; Blackstone is expected to provide $750 million toward development. UBS sees the asset as a potential growth driver beyond 2030. J&J to Boost Ophthalmology Pipeline With $2.2B Ollin Acquisition UBS on Ollin as a Growth Driver
  • Neutral Sentiment: The Ollin acquisition strengthens J&J’s ophthalmology portfolio, but its late-stage drug would enter a competitive market and still faces clinical and commercial execution risks. J&J Bets $2.2B on Ollin’s Vision Loss Drug
  • Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J related to its talc baby powder, adding to ongoing litigation concerns. Separately, Pomerantz LLP said it is investigating claims on behalf of J&J investors; an investigation is not a finding of wrongdoing, but may add uncertainty. Louisiana Appeals Court Upholds Damages in Mesothelioma Case Pomerantz Investor Alert

About Johnson & Johnson

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Featured Articles

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.